Lannett Company develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. The company was founded in 1942 and is based in Philadelphia, Pennsylvania.
LCI Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Lannett Co Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Lannett Co Inc ranked in the 56th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 53%. The most interesting components of our discounted cash flow analysis for Lannett Co Inc ended up being:
The company's debt burden, as measured by earnings divided by interest payments, is 0.27 -- which is good for besting only 24.78% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
28% of the company's capital comes from equity, which is greater than merely 11.93% of stocks in our cash flow based forecasting set.
Lannett Co Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Lannett Co Inc? See UNH, ACIU, REGN, EGRX, and UTHR.
If we have learned anything from the COVID-19 pandemic of 2020 it is the past is not a predictor of the future and that the only certainty is uncertainty. Yet, for businesses, the effort to forecast the future remains a much sought-after goal and often pursued through data from the...
Investment Thesis We have been bullish on Lannett (LCI) because of its achievement the last 12 months in filling the $200M void that Levo had created, and also its roadmap to $1B in revenue by 2025. Today, the company hits a roadblock. The gap remains large as competitive pressure has...
Lannett Company, Inc. (NYSE: LCI) today announced that it has launched Mexiletine Hydrochloride Capsules 150 mg, 200 mg and 250 mg, a partnered product. Mexiletine Hydrochloride Capsules is the AB-rated generic equivalent to Mexitil® Capsules of Boehringer Ingelheim.